Preoperative evaluation with T-staging system for hilar cholangiocarcinoma

Table 1 Revised preoperative T staging system for patients with hilar cholangiocarcinoma

T Stage	Description
T1	Tumor involving biliary confluence ± unilateral extension to 2° biliary radicles
	No liver atrophy or portal vein involvement
T2	Tumor involving biliary confluence ± unilateral extension to 2° biliary radicles with ipsilateral portal vein involvement ± ipsilateral hepatic lobar atrophy
	No main portal vein involvement
T3	Tumor involving biliary confluence + bilateral extension to 2° biliary radicles; OR unilateral extension to 2° biliary radicles with controlateral portal vein involvement; OR unilateral extension to 2° biliary radicles with controlateral hepatic lobar atrophy; ralateral hepatic lobar atrophy; phy; OR main or bilateral portal venous involvement

Table 2 Resectability, incidence of margins negative and metastatic disease after staging by T stage

T Stage	Operative modus			Margins		Metastatic disease
	Resected	Drainage	Biopsy	Negative	Positive	Negative	Positive
T1 (n = 39)	29 (74.4)	8 (20.5)	2 (5.1)	22 (75.9)	7 (24.1)	24 (61.5)	15 (38.5)
T2 (n = 15)	9 (60.0)	4 (26.7)	2 (13.3)	3 (33.3)	6 (66.7)	7 (46.7)	8 (53.3)
T3 (n = 31)	2 (6.5)	15 (48.4)	14 (45.1)	0 (0)	2 (100)	9 (30.0)	22 (70.0)
χ2 value	35.5			8.8		7.3
P value	0.000			0.012		0.026

The percentages indicate the proportion of patients within each stage grouping or of the total number of patients. Metastatic disease refers to metastases to N2-level lymph nodes or to distant sites. Median survival was calculated for all patients, including those who died perioperatively.

Table 3 Margins negative, complication, operative mortality and survival based on in-continuity hepatic resection

Hepatic resection	n	Margins		Operativemortality, n (%)	Median survival, mo
		Negative,n (%)	Complication,n (%)
In-continuity Hepatic Resection	28	21 (75)	16 (57)	3 (11)	28
No Hepatic Resection	12	4 (33)	4 (33)	1 (8)	18